Shares of Orchid Pharma Ltd. surged 10% on Wednesday, July 8, after the pharmaceutical major announced its entry into the Russian market by signing signed an exclusive licensing and supply agreement with Russia's leading drugmaker Pharmasyntez JSC for a multi-drug resistant bacterial infections antibiotic Exblifep (cefepime/enmetazobactam). The novel drug is a combination antibiotic for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gramnegative bacterial pathogens, as per Orchid Pharma.
According to the pharma major, the deal will introduce Orchid's Exblifep to patients in Russia, opening up a market opportunity that the Indian drugmaker estimates at about $178 million over the first decade. The landmark deal marks the commercialisation of Exblifep in Russian market. With the signing of the deal, shares of Orchid Pharma surged 10% in trade to hit an intraday high of Rs 1,047, nearing the 52-week high mark of Rs 1,094 apiece on the NSE. The triple-digit PE pharma stock traded above the Rs 1,000-mark with the surge in the intraday share price, defying the Nifty 50 benchmark index.
ALSO READ: IOC, BPCL, HPCL Shares Drop 4% As Crude Oil Price Climbs 3% To $76 Per Barrel As US Strikes Iran
Orchid Pharma Share Price Intraday
Pharmasyntez will receive exclusive rights to register and commercialise Exblifep in Russia, subject to approval from the Russian health ministry. ''Pharmasyntez's deep reach into the Russian hospital procurement system makes them the right partner to ensure this medicine gets to the clinicians and patients who need it,'' said Manish Dhanuka, Managing Director, Orchid Pharma Ltd.
Orchid Pharma will be responsible for manufacturing and supplying the finished dosage form of the drug. This structure allows Orchid to leverage Pharmasyntez's deep reach into the Russian hospital procurement system while focusing on its core manufacturing strengths. “Antimicrobial resistance is one of the most significant challenges facing modern medicine, making the development of new antibiotics critical,'' said Natalia Malykh, Vice President, Business Development, Pharmasyntez group.
''This licensing agreement with Pharmasyntez enables Russian patients to gain access to modern antibacterial therapy.” said Malykh. The antibiotic is developed to address the growing clinical challenge posed by ESBL-producing Gram-negative bacteria in serious hospital infections. It is positioned as a carbapenem-sparing therapy, offering physicians an alternative tool against infections driven by ESBL-producing pathogens, which are increasingly associated with antibiotic resistance.
''The decade-long partnership presents a substantial financial opportunity, with a potential value of approximately $178 million over the first 10 years,'' said Orchid Pharma in its regulatory filing to the stock exchanges. Exblifep's commercialization is not just a win for Orchid Pharma, but a landmark moment for India's broader pharmaceutical innovation story.
For Orchid, Exblifep holds the distinction of being the first new chemical entity originating from an Indian pharmaceutical company to successfully secure approvals from both the US Food and Drug Administration (US FDA) and the European Medicines Agency (EMA). The product is also included in treatment guidelines issued by IDSA and EUCAST.
Exblifep's Global Value Potential
The Russian partnership is just one piece of a much larger global strategy. Exblifep has an estimated lifetime sales potential of $1 to $2 billion. Orchid Pharma is actively engaged in ongoing licensing discussions to introduce the drug to other major markets, including the US, Japan, Latin America (LATAM), and Southeast Asia. The company projects that the antibiotic will hit its peak sales around four to five years post-launch.
Expanding into US Market
Looking beyond licensing, Orchid Pharma has ambitious plans to directly enter the US sterile formulations market. The company is preparing to invest in enhanced fill-finish and formulation capabilities to support this move. The target opportunity in the US market alone is estimated to be around $1.2 billion, representing a massive avenue for future revenue generation.
FY27 Financial and Growth Targets
Fueled by these international expansion efforts, Orchid Pharma has outlined strong financial projections for the upcoming years. For FY27, the company is targeting a revenue growth rate of 10% to 15%, alongside an expected EBITDA margin of approximately 12%. This continued financial growth is anticipated to be driven primarily by strategic entries and deeper market penetration in Rest of World (ROW) markets.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
